We are live on ! Find out more
EUCRU

Eucrates Biomedical Acquisition Corp. Unit
EUCRU

Delisted

EUCRU was delisted on the 26th of April, 2023.

Back to rankings

14 hedge funds and large institutions have $27.1M invested in Eucrates Biomedical Acquisition Corp. Unit in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 17 → 14 (-3)

34% less capital invested

Capital invested by funds: $41.2M → $27.1M (-$14.1M)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$9.95M
2
HM
HealthCor Management
New York
-$2.32M
3
RSCM
Rock Springs Capital Management
Maryland
-$2.05M
4
GCL
Glazer Capital LLC
New York
-$791K
5
MF
Magnetar Financial
Illinois
-$40.2K

EUCRU Hedge Fund Activity: Q4 2021 in Review

14 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q4 2021, worth a combined $27.1M — down 34% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of EUCRU and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 0 added.

The largest seller was Deerfield Management, exiting entirely with an estimated $9.95M sold.

  • 14 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q4 2021, down from 17 in Q3 2021.
  • Funds reported $27.1M of Eucrates Biomedical Acquisition Corp. Unit stock for Q4 2021, down 34% quarter-over-quarter.
  • 2 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q4 2021 and 5 closed out, a net change of -3 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q4 2021 was Deerfield Management, an estimated $9.95M sold.

Based on aggregated 13F filings for Q4 2021.